Teva: The Post-Allergan Deleveraging Cycle
Teva paid $40.5 billion for Allergan Generics in 2016 and watched approximately $50 billion in market value evaporate. Eight years and three CEOs later, the deleveraging cycle is two-thirds complete.
Teva Pharmaceutical Industries paid $40.5 billion for the Allergan generics business in 2016. The deal collapsed the company. The deal also defined the decade that followed. Eight years and three CEOs later, Teva is roughly half-deleveraged from the post-acquisition peak — and the question for 2026 is whether the company can complete the deleveraging cycle and pivot to growth before the next debt wall.
The original sin
Teva — Israel's largest pharmaceutical company, headquartered in Petach Tikva — entered 2016 as the global leader in generic drug manufacturing with approximately $20 billion in annual revenue. Then-CEO Erez Vigodman bought Allergan Generics from Allergan plc for $33.4 billion in cash plus stock — a price that included regulatory-mandated divestitures and represented one of the largest pharmaceutical M&A transactions of the 2010s. The deal closed in August 2016. By the end of 2017, Teva had written down approximately $17 billion of the acquired goodwill. The stock collapsed from approximately $68 in mid-2015 to approximately $11 in late 2017.
The diagnosis: Teva had overpaid for a US generics business at the peak of the generics consolidation cycle, just as US wholesaler concentration and direct-manufacturing competition began compressing generic pricing. Net debt peaked at approximately $35 billion. The combined company carried more debt than the post-deal Teva was earning in EBITDA. Multiple credit downgrades followed. Then the US opioid litigation overhang — Teva manufactured fentanyl patches and other controlled-substance generics — added a multibillion-dollar liability layer.
The Schultz era: 2017–2023
Kåre Schultz, the former Lundbeck CEO, took over Teva in November 2017. Schultz executed a textbook deleveraging playbook: roughly 14,000 layoffs, divestiture of non-core assets, plant closures, working capital optimization, and an aggressive shift from generics-only to innovative branded drugs. By the end of Schultz's tenure in 2023, net debt had declined from approximately $32 billion to approximately $19 billion. The opioid litigation settled for approximately $4.25 billion (less than analysts had feared). The branded portfolio — Austedo for Huntington's disease and tardive dyskinesia, Ajovy for migraine prevention — became the growth engine.
The Francis era: 2023–present
Richard Francis, the former Sandoz CEO, succeeded Schultz in January 2023 and introduced the "Pivot to Growth" strategic framework. Three pillars: deliver on innovative branded drugs, accelerate the biosimilars business, and continue financial discipline. The framework signals a structural shift — Teva is no longer running the deleveraging playbook as the sole priority; growth is back in scope. Net debt as of recent quarters sits at approximately $17–18 billion. Net debt to EBITDA has compressed from the post-deal peak of approximately 8x to approximately 3.5x — within the range that investment-grade credit rating committees consider for upgrade conversation.
The innovative branded portfolio is performing. Austedo crossed $1 billion in annual revenue in 2023 and is on a trajectory toward $2.5 billion by 2027. Uzedy, the long-acting injectable schizophrenia treatment, launched in 2023 and is building presence. Ajovy continues to grow. The biosimilars business — including key launches of biosimilar Stelara (in partnership with Alvotech) and biosimilar Humira — has scaled meaningfully.
The remaining capital structure question
Teva carries debt across multiple tranches with maturities through the early 2030s. The 2027 and 2028 maturity walls are manageable at current cash generation, but a credit-cycle deterioration would compress the deleveraging trajectory. Teva's revenue stack — branded innovative + biosimilars + traditional generics — is more diversified than it was at the deal-peak overconcentration, but the company remains structurally exposed to US generic pricing and to the timing of innovative-branded patent cliffs.
The Israeli implication
Teva trades on NASDAQ (TEVA) and on the Tel Aviv Stock Exchange — and it is the only Israeli company in the TASE 35 from the pharmaceutical sector. Its capitalization has moved from a peak of approximately $70 billion in 2015 to a current ~$18 billion. The destruction in market value — roughly $50 billion — is the largest aggregate value-destruction event in modern Israeli public-equity history.
For Israeli institutional investors — Mivtachim, Menorah, Migdal, Harel, Phoenix — Teva's deleveraging is the largest single position management challenge of the post-2016 era. The pension funds that maintained Teva exposure through the collapse have substantially recovered position via the Austedo-driven recovery. The institutional read is that Teva is no longer a turnaround story but a normal pharmaceutical sector position — meaningful capital structure overhang, but with a defined recovery path and a viable innovative pipeline.
The structural read
Teva is the institutional case study in Israeli M&A overreach. The Allergan deal is taught as a cautionary tale in Israeli MBA programs and inside Israeli corporate boards. The deleveraging cycle has been competently executed. The growth pivot is plausible but not yet proven. The company's importance to Israel — as the largest pharmaceutical employer, the largest manufacturing footprint outside the defense sector, and a top-three Israeli employer overall — gives the trajectory weight beyond the stock price.
The next deleveraging milestone is the 2027 maturity wall. Clearing it without refinancing pressure would mark the formal end of the post-Allergan cycle and the beginning of whatever Teva becomes next.